Today we are delighted to announce our strategic alliance agreement with Infopoly to advance our in-house in-silico technology to improve the translational development of new medicines pain and beyond. Find out more in our announcement below.
eptivA Therapeutics Ltd.
Biotechnology Research
A clinical stage biotech company utilising novel Personalized Analgesics® research to create precision pain medicines
About us
Eptiva Therapeutics is a clinical stage Biotech company transforming the way pain is treated with PERSONALIZED ANALGESICS®. We have invented novel in silico research methods to create the first precision medicine approach to pain.
- Website
-
www.EptivaTx.com
External link for eptivA Therapeutics Ltd.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Oxford
- Type
- Privately Held
Locations
-
Primary
Get directions
Oxford, GB
Employees at eptivA Therapeutics Ltd.
Updates
-
We are looking forward to work with Dr Matt Parker and colleagues at University of Surrey following his award from the Royal Society to further research our personalized analgesic cholecalciferol project for patients suffering #chronicpain.
Congratulations to Dr Matt Parker for being awarded a Short Industry Fellowship from the Royal Society. Together with EptivA Therapeutics, Matt will be researching new personalised medication for those suffering from chronic pain. Find out more about this news on our website: https://ow.ly/A1ZA50TzOGi
-
-
eptivA Therapeutics Ltd. reposted this
Transforming the way pain is treated with Personalized Analgesics® | CEO Co-Founder | 30 years Pharma R&D experience I PhD MSc Neuroscientist | Inventor Pain Cloud® in silico Network Biology
We are delighted to announce our new partnership with Dr Matt Parker and University of Surrey aimed at advancing the development of chronic pain medicines. Dr Parker has recently been awarded a Short Industry Fellowship from the #RoyalSociety to work with eptivA Therapeutics Ltd. researching a new personalised medication for those suffering from chronic pain. During this partnership, Surrey scientists, in collaboration with eptivA, will examine the effectiveness of cholecalciferol as a non-opioid pain reliever. This builds on findings from eptivA, which used its Pain Cloud® research platform to uncover links between the Vitamin D receptor gene and specific pain conditions. EptivA employs a data-driven, personalised approach to pain management. Central to this research partnership is their innovative new Pain Cloud® platform, developed in collaboration with biotech firm Infopoly. This platform uses in silico modelling to validate new targets for pain research and, crucially, identify the most suitable patient groups for clinical development. Link to full press release: https://lnkd.in/eRNfXJ7W
-
-
eptivA Therapeutics Ltd. reposted this
Transforming the way pain is treated with Personalized Analgesics® | CEO Co-Founder | 30 years Pharma R&D experience I PhD MSc Neuroscientist | Inventor Pain Cloud® in silico Network Biology
Current pain treatments only work in a small subpopulation of patients and 99% of new analgesic drug research fails in clinical development. And that’s not good enough. That’s why we discuss the challenges of traditional pain R&D and target validation in our article. Plus, we explore how Pain Cloud®, EptivA’s B2B platform, can help change things for the better. #PainRandD #PainResearch #TargetValidation #ChronicPain
-
With Pain Cloud®, eptivA Therapeutics Ltd. are changing the way that analgesics development is conducted. Working in partnership with Infopoly Ltd., we have created Pain Cloud®, an in-silico method, based on network biology principles, linking open access ‘large-data’ for unbiased ‘omic’ enrichment with Pain Cloud’s Proprietary Pain Landscape®, which hosts a wide range of data on over 1,000 distinct pain conditions. Follow our new Pain Cloud® LinkedIn page for our latest updates and news. #PainResearch #ResearchandDevelopement #Analgesics #ChronicPain
Pain Cloud® is the result of a collaboration between eptivA Therapeutics Ltd. and Infopoly, who have created this advanced solution for Pain Research. To address the challenges faced by pain researchers during R&D of pain therapeutics – including cost and 1% success rate – EptivA Therapeutics, in a strategic partnership with digital technology experts Infopoly Ltd., has developed Pain Cloud®. This transformative new target validation in-silico platform is designed to assist companies that develop analgesics increasing clinical development success. Learn more about this brand-new technology working to make analgesics development quicker, less expensive, and more successful below ⬇️ #PainResearch #ResearchandDevelopement #Analgesics #ChronicPain
Pain Cloud® Launch: A Collaboration between EptivA and Infopoly Ltd., creating an advanced solution to Pain Research.
Pain Cloud® on LinkedIn
-
eptivA Therapeutics Ltd. reposted this
Transforming the way pain is treated with Personalized Analgesics® | CEO Co-Founder | 30 years Pharma R&D experience I PhD MSc Neuroscientist | Inventor Pain Cloud® in silico Network Biology
Great news to hear that eptivA Therapeutics Ltd.'s 'Late Breaking Poster Submission' was accepted for presentation at the #IASP World Congress on #Pain. We will be sharing our latest research on 'PainCLOUD® - A Novel in-silico Network Biology Methodology to Develop Personalized Analgesics®'. Come by to see how #PainCLOUD® can bridge the gap in #translational #research and increase success in #analgesic development.
-